Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk MDS Relapsed/Refractory to ESA Treatment
NCT02598661Phase 3Active, not recruiting
- Sponsor
- Geron Corporation
- Start
- Jan 2016
- Primary completion
- Oct 2023
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of imetelstat in myelodysplastic syndrome (MDS) (7 arms), sponsored by Geron Corporation. Primary endpoint: Percentage of Participants Without Any Red Blood Cell (RBC) Transfusion During Any Consecutive 8-Weeks Period up to 5 years. Started Jan 2016; status: active, not recruiting.
02
Drugs
imetelstat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02598661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598661.